Phoenix, AZ (openPR) 7 October 2010

The International Genomics Consortium (IGC) announced today that it successfully in competition and won two prestigious national orders of the National Cancer Institute (NCI) until offer samples of cancerous tissue for analysis in the Cancer Genome Atlas Project (TCGA) and the second to continue to serve as a resource base of biological samples (BCR) of TCGA. IGC held a critical mass of tissue source Site Network TCGA under a contract with a value of, and operate a 360 880 BCR in the next five years in a contract worth 521 401. IGC expand their network to help hospitals, national research project for the expression developed for oncology (Expo) to accumulate samples of cancer and related blood of at least 17 different types of cancer. These cancers untreated complete full analysis performed on them by genomic sequencing centers and characterization of the TCGA.

TCGA is one of the largest initiatives to date to a large number of cancers with many different analysis of genomic sequencing studies of methylation analyzed. Genomics plans of each type of cancer is available on the web for all researchers have access to discoveries of the translation. TCGA plans analyzed 500 tumors of all types of cancer studied by the program and provide data on the clinical results and commented on for a comprehensive genomic analysis without any restriction of intellectual property. IGC expects to record a part of each sample, the TCGA provides possibly the translation of discoveries to accelerate, to get the patient care in the TCGA work separate settings. The price of the IGC also complement the current leadership role as a resource TCGA basic biological samples, a â? Grand Central Station? for the project? s sample and the extraction of molecular analytes. For more information TCGA http://cancergenome.nih.gov/ be found.

more solidified Arizona? s started national role in tissue and diagnostics translational and confirm the success of the exhibition Visionary IGC IGC national project in 2003 and has most recently as a result of criticism from the Science Foundation Arizona funding was sustained. Expo has managed to collect over 15,000 samples of cancer more than 4,000 cancer patients nationally.

â? It is a great honor for Arizona? s Intergovernmental Conference to remain a part of the management of such a project on cancer history? Said Robert Penny, MD, Ph.D., IGCA? CEO and Principal Investigator for the components of the TSS and BCR TCGA. â? We have to find an independent responsibilities, paths and IGC reflect better faster patients.â the IGC remaining tissue and blood in our biobank in better diagnostics and therapies for cancer?

IGC succeeded in creating targeted in cooperation with two national organizations of physicians, U.S. Oncology and AmeriPath (a division of Quest Diagnostics), the collections of cancer tissue in hospitals in the United States for her project Expo, the two organizations significantly The success of the current site of the tissue TCGA Source Network Award. It is expected that 18 hospitals across the country will help to provide samples of cancerous tissue IGC TCGA.

â? We are pleased that the Government Conference together with the U.S. Oncology to the NCI in the acceleration of personalized medicine for our cancer patients, support is â? Said Lloyd Everson, MD, Vice President of U.S. Oncology.

Quest Diagnostics has a long-time assistant with the IGC and its initiatives in translational diagnostics and biobanks, “said Dr. Jeffrey Mossler, Director of Anatomic Pathology at Quest Diagnostics.” This is an excellent initiative on translational research in genomics clinical trials would accelerate. “

David Mallery, JD, MBA, IGCA? s President noted that one? Arizona? Leadership in supporting our major pilot studies were decisive? to allow the start of the IGC for the competition and bring these projects to the state. â? Intergovernmental Conference on Maricopa County, the City of Phoenix, Caris Life Sciences, Arizona Science Foundation, the Flinn Foundation and several pharmaceutical companies, financial support and leadership have made available to the IGC and our initiatives in the past.

Media Contact: Joe Paulauskas Ph.D. (602) 850 â? 7000

About IGC

The International Genomics Consortium (IGC) is a charitable foundation for medical research in place to extend the discoveries of the Human Genome Project and other systematic sequencing efforts by combining world-class research genomics, bioinformatics, and diagnostic technologies in the fight against cancer and other complex genetic diseases. IGC offers many common unmet needs, including: standardizing the collection of well-accepted tissue of interest, the molecular characterization of these tissues, and standardization in the representation of the results. IGC is participating in the transition of genetic discoveries to improve patient care and improving the speed with which the new drug, diagnostic, prognostic and predictive tests and new therapies are developed. For more information, visit www.intgen.org.


About U.S. Oncology


U.S. Oncology, Inc. is the nation? s leading integrated oncology. By uniting the cancer community and the largest research network in America, U.S. Oncology expands patient access to quality health care and advances in the science of cancer treatment. Based in The Woodlands, Texas, is a U.S. Oncology with more than 1,300 community-based oncologists affiliated and works with patients, hospitals, health insurance and medical industry in all phases of cancer research and the continuum of delivery. By promoting the use of innovative technologies, clinical research, medicine based on evidence and sharing of best practices to improve U.S. Oncology patient outcomes and better patient experience. For more information, visit www.usoncology.com.

About Quest Diagnostics

Quest Diagnostics is the leading provider of testing, diagnostic information and services that patients and doctors must make decisions in health care quality. The company offers the broadest access to diagnostic testing services through a network of laboratories and patient service centers, and provides advice in their interpretation of medical and scientific details. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced solutions for information technology in healthcare to improve patient care. For more information about the company, see www.QuestDiagnostics.com.


>

clear = “all”
Conversion Phoenix